Zydus Lifesciences Ltd. announcements
In the twelve months since 23 September 2025 Zydus Lifesciences Ltd. made 207 announcements to NSE under Regulation 30: 65 press release, 40 general updates, 24 copy of newspaper publication, 22 analysts/institutional investor meet/con. call updates, 12 updates, 6 investor presentation. The latest, on 22 September 2026, was filed under copy of newspaper publication; the table carries the company's own summary of each and the PDF.
| Date | Category | What the company told the exchange | Filing |
|---|---|---|---|
| 22 September 2026 | Copy of Newspaper Publication | Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication | |
| 11 September 2026 | Credit Rating | Zydus Lifesciences Limited has informed the Exchange about Credit Rating | |
| 11 September 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Zydus Lifesciences Limited has informed the Exchange about Schedule of meet | |
| 9 September 2026 | Copy of Newspaper Publication | Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication | |
| 5 September 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 1 September 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 31 August 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 31, 2026, titled "Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH". | |
| 26 August 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 25 August 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 24 August 2026 | Updates | Zydus Lifesciences Limited has informed the Exchange regarding 'Disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015'. | |
| 23 August 2026 | Investor Presentation | Zydus Lifesciences Limited has informed the Exchange about Investor Presentation | |
| 21 August 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 21 August 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 21, 2026, titled "Zydus announces final approval from the USFDA for Ascorbic Acid Injection with 180-Days CGT exclusivity". | |
| 18 August 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Zydus Lifesciences Limited has informed the Exchange about Transcript | |
| 17 August 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Zydus Lifesciences Limited has informed the Exchange about Schedule of meet | |
| 12 August 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Zydus Lifesciences Limited has informed the Exchange about Schedule of meet | |
| 12 August 2026 | Copy of Newspaper Publication | Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication | |
| 11 August 2026 | Change in Director(s) | Zydus Lifesciences Limited has informed the Exchange regarding Change in Director(s) of the company. | |
| 11 August 2026 | Shareholders meeting | Zydus Lifesciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 11, 2026. Further, the company has submitted the Exchange a copy of Scrutinizers report along with voting results. | |
| 11 August 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Zydus Lifesciences Limited has informed the Exchange about Link of Recording | |
| 11 August 2026 | Updates | Zydus Lifesciences Limited has informed the Exchange regarding 'Reporting of violation of Code of Conduct under SEBI (Prohibition of Insider Trading) Regulations, 2015'. | |
| 11 August 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 11, 2026, titled "Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency- Associated Lung Disease (AATD-LD)". | |
| 11 August 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 11, 2026, titled "Press Release". | |
| 11 August 2026 | Investor Presentation | Zydus Lifesciences Limited has informed the Exchange about Investor Presentation | |
| 11 August 2026 | Outcome of Board Meeting | Zydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026. | |
| 10 August 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 10, 2026, titled "Zydus launches REVAHALE , India s first once-daily nebulised LAMA for COPD". | |
| 10 August 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Zydus Lifesciences Limited has informed the Exchange about Schedule of meet | |
| 4 August 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 04, 2026, titled "Zydus announces Final Approval from the USFDA for Indocyanine Green for Injection with 180-Days CGT exclusivity". | |
| 4 August 2026 | Copy of Newspaper Publication | Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication | |
| 4 August 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Zydus Lifesciences Limited has informed the Exchange about Schedule of meet | |
| 4 August 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Zydus Lifesciences Limited has informed the Exchange about Schedule of meet | |
| 1 August 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 01, 2026, titled "Zydus receives EIR from the USFDA for its injectable facility with VAI classification". | |
| 30 July 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Zydus Lifesciences Limited has informed the Exchange about Schedule of meet | |
| 29 July 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 25 July 2026 | Disruption of Operations | Zydus Lifesciences Limited has informed the Exchange about Disruption of Operations | |
| 23 July 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 23, 2026, titled "Zydus receives approval for Phase III trial of Desidustat in patients with Sickle Cell Disease, to be conducted in collaboration with ICMR". | |
| 14 July 2026 | News Verification | The Exchange has sought clarification from Zydus Lifesciences Limited with respect to recent news item captioned Delhi HC Temporarily Restricts Supply Of Zydus Cancer Drug Ikra In AbbVie Patent Dispute. The response from the Company is attached. | |
| 14 July 2026 | News Verification | The Exchange has sought clarification from Zydus Lifesciences Limited with respect to recent news item captioned Delhi HC Temporarily Restricts Supply Of Zydus Cancer Drug Ikra In AbbVie Patent Dispute. The response from the Company is awaited. | |
| 11 July 2026 | Copy of Newspaper Publication | Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication | |
| 10 July 2026 | Shareholders meeting | Zydus Lifesciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 11, 2026 | |
| 9 July 2026 | Copy of Newspaper Publication | Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication | |
| 8 July 2026 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | Zydus Lifesciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 | |
| 4 July 2026 | Copy of Newspaper Publication | Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication | |
| 3 July 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 03, 2026, titled "Zydus signs MoU with Apollo Hospitals to expand access to the Shield Multi-Cancer Detection test (MCD) in India". | |
| 29 June 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 26 June 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about Joint Venture in Sri Lanka | |
| 25 June 2026 | Trading Window | Zydus Lifesciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 | |
| 20 June 2026 | Updates | Zydus Lifesciences Limited has informed the Exchange regarding 'Disclosures under Insider Trading Regulations'. | |
| 19 June 2026 | Updates | Zydus Lifesciences Limited has informed the Exchange regarding 'Extinguishment Certificate'. | |
| 18 June 2026 | Copy of Newspaper Publication | Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication | |
| 16 June 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 16 June 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated Jun 16, 2026, titled "Zydus announces the successful completion of acquisition of Assertio Holdings". | |
| 11 June 2026 | Copy of Newspaper Publication | Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication | |
| 9 June 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 3 June 2026 | Copy of Newspaper Publication | Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication | |
| 3 June 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 1 June 2026 | Buyback | Zydus Lifesciences Limited has informed the Exchange about Buyback | |
| 1 June 2026 | Buyback | Zydus Lifesciences Limited has informed the Exchange about Buyback | |
| 31 May 2026 | Buyback | Zydus Lifesciences Limited has informed the Exchange about Buyback | |
| 28 May 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Zydus Therapeutics New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA". | |
| 28 May 2026 | Buyback | Zydus Lifesciences Limited has informed the Exchange about newspaper publication of addendum to Public Announcement for Buyback | |
| 27 May 2026 | Buyback | Zydus Lifesciences Limited has informed the Exchange about addendum to the Public Announcement for the buyback of equity shares | |
| 27 May 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 26 May 2026 | Updates | Zydus Lifesciences Limited has informed the Exchange regarding 'Disclosure under SEBI (PIT) Reg 2015'. | |
| 24 May 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Zydus Lifesciences Limited has informed the Exchange about Transcript | |
| 23 May 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Zydus Lifesciences Limited has informed the Exchange about Schedule of meet | |
| 21 May 2026 | Updates | Zydus Lifesciences Limited has informed the Exchange regarding 'Public Announcement on Buyback'. | |
| 21 May 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Zydus Lifesciences Limited has informed the Exchange about Schedule of meet | |
| 20 May 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 20 May 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 20 May 2026 | Copy of Newspaper Publication | Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication | |
| 19 May 2026 | Buyback | Zydus Lifesciences Limited has informed the Exchange about Buyback | |
| 19 May 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Zydus Lifesciences Limited has informed the Exchange about Link of Recording | |
| 19 May 2026 | Updates | Zydus Lifesciences Limited has informed the Exchange regarding 'Intention of promoters to participate in buyback'. | |
| 19 May 2026 | Record Date | Zydus Lifesciences Limited has informed the Exchange that Record date for the purpose of Buyback is 29-May-2026. | |
| 19 May 2026 | Record Date | Zydus Lifesciences Limited has informed the Exchange that Record date for the purpose of Dividend is 24-Jul-2026. | |
| 19 May 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 19, 2026, titled "Press Release". | |
| 19 May 2026 | Investor Presentation | Zydus Lifesciences Limited has informed the Exchange about Investor Presentation | |
| 19 May 2026 | Change in Director(s) | Zydus Lifesciences Limited has informed the Exchange regarding Change in Director(s) of the company. | |
| 19 May 2026 | Outcome of Board Meeting | Zydus Lifesciences Limited has informed the Exchange regarding Outcome of Board Meeting held on May 19, 2026. | |
| 19 May 2026 | Dividend | Zydus Lifesciences Limited has informed the Exchange that Board of Directors at its meeting held on May 19, 2026, recommended Final Dividend of Rs. 1.00 per equity share. | |
| 19 May 2026 | Outcome of Board Meeting | Zydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. | |
| 15 May 2026 | Disclosure under SEBI Takeover Regulations | Zydus Lifesciences Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. | |
| 13 May 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 13 May 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 13 May 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Zydus Lifesciences Limited has informed the Exchange about Schedule of meet | |
| 13 May 2026 | Cessation | Zydus Lifesciences Limited has informed the Exchange regarding Cessation of Mr Apurva S. Diwanji as Non- Executive Independent Director of the company w.e.f. May 12, 2026. | |
| 6 May 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 06, 2026, titled "USFDA inspection concludes at Zydus' Biologics Injectable plant, Ahmedabad". | |
| 5 May 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 1 May 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 1 May 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 30 April 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 25 April 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 25, 2026, titled "Zydus receives approval from DCGI to initiate Phase III trials of Zintrodiazine, a novel anti-malarial candidate". | |
| 22 April 2026 | Copy of Newspaper Publication | Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication | |
| 22 April 2026 | Copy of Newspaper Publication | Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication | |
| 16 April 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 16, 2026, titled "Zydus receives EIR for oncology injectable manufacturing facility in SEZ1, Ahmedabad". | |
| 16 April 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 10 April 2026 | Disclosure under SEBI Takeover Regulations | Zydus Lifesciences Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. | |
| 10 April 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 8 April 2026 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | Zydus Lifesciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 | |
| 8 April 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 08, 2026, titled "Zydus receives final approval from USFDA for Dapagliflozin Tablets, 5 mg and 10 mg". | |
| 6 April 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 1 April 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 31 March 2026 | Change in Management | Zydus Lifesciences Limited has informed the Exchange about change in Management | |
| 27 March 2026 | Updates | Zydus Lifesciences Limited has informed the Exchange regarding 'Reporting of violation of Code of Conduct under SEBI (Prohibition of Insider Trading) Regulations, 2015'. | |
| 26 March 2026 | Trading Window | Zydus Lifesciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 | |
| 25 March 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 21 March 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 21, 2026, titled "Zydus launches Semaglutide Injection in an innovative, reusable multi-dose pen device in India". | |
| 19 March 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 19, 2026, titled "Zydus launches Aerolife Mini , to simplify inhaler use for asthma and COPD patients". | |
| 18 March 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 18, 2026, titled "Zydus and Torrent Pharma sign licensing agreement to co-market innovative Semaglutide Injection in India". | |
| 17 March 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 17, 2026, titled "Zydus and Lupin sign licensing agreement for co-marketing innovative Semaglutide Injection in India". | |
| 16 March 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 16, 2026, titled "Sentynl Therapeutics Enters into Agreement with PRG S&T to License Molecule for Hutchinson-Gilford Progeria Syndrome". | |
| 14 March 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 14, 2026, titled "Zydus new drug discovery, Desidustat licensed to China Medical System Holdings receives approval from NMPA of China". | |
| 13 March 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 13, 2026, titled "Zydus receives final approval from USFDA for Cevimeline Hydrochloride Capsules 30mg". | |
| 12 March 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 12, 2026, titled "Zydus expands companion diagnostics portfolio with the launch of AI-powered Continuous Glucose Monitor DiasensTM and GlucoLiveTM". | |
| 28 February 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 28, 2026, titled "Zydus receives final approvals from USFDA for Ivermectin Tablets USP, 3 mg and Dapsone Tablets USP, 25 mg and 100 mg". | |
| 27 February 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 27, 2026, titled "Zydus Lifesciences announces successful clinical development of Pembrolizumab biosimilar FYB206, marking a milestone toward USFDA filing". | |
| 25 February 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 25, 2026, titled "Zydus plans to launch innovative Semaglutide Injection in India on Day 1 of patent expiry, expanding patient access to GLP-1 therapy". | |
| 25 February 2026 | Copy of Newspaper Publication | Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication | |
| 19 February 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 19, 2026, titled "Closure of USFDAinspection at Zydus Injectable plant at Ahmedabad". | |
| 19 February 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 19, 2026, titled "Zydus launches biosimilar Aflibercept 2 mg ANYRA for advancing ophthalmic care ". | |
| 18 February 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 18, 2026, titled "Zydus receives final approval from USFDA for Bosentan tablets for oral suspension, 32 mg". | |
| 18 February 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Zydus Lifesciences Limited has informed the Exchange about Schedule of meet | |
| 17 February 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 17, 2026, titled "Zydus launches PEPAIR, a first in India, affordable, drug-free, handheld device for better respiratory health". | |
| 15 February 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Zydus Lifesciences Limited has informed the Exchange about Transcript | |
| 14 February 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 14, 2026, titled "Zydus receives final approval from USFDA for Ammonium Lactate Cream, 12%". | |
| 12 February 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 10 February 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Zydus Lifesciences Limited has informed the Exchange about Link of Recording | |
| 10 February 2026 | Copy of Newspaper Publication | Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication | |
| 9 February 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 09, 2026, titled "Press Release". | |
| 9 February 2026 | Investor Presentation | Zydus Lifesciences Limited has informed the Exchange about Investor Presentation | |
| 9 February 2026 | Updates | Zydus Lifesciences Limited has informed the Exchange regarding 'Board comments on penalties levied by BSE and NSE'. | |
| 9 February 2026 | Outcome of Board Meeting | Zydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025. | |
| 6 February 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 06, 2026, titled "Zydus receives USFDA Orphan Drug Designation (ODD) for Desidustat for the treatment of Sickle Cell Disease". | |
| 4 February 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 04, 2026, titled "Zydus receives tentative approval from USFDA for Dapagliflozin Tablets, 5 mg and 10 mg". | |
| 4 February 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Zydus Lifesciences Limited has informed the Exchange about Schedule of meet | |
| 31 January 2026 | Change in Management | Zydus Lifesciences Limited has informed the Exchange about change in Management | |
| 30 January 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Zydus Lifesciences Limited has informed the Exchange about Schedule of meet | |
| 23 January 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 23, 2026, titled "Outcome of USFDA inspection". | |
| 22 January 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 22, 2026, titled "Zydus launches the world s first biosimilar of Nivolumab, Tishtha , in India to treat multiple cancers". | |
| 20 January 2026 | Updates | Zydus Lifesciences Limited has informed the Exchange regarding 'Revision in ESG Rating'. | |
| 17 January 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 15 January 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 15 January 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 15, 2026, titled "Zydus receives final approval from USFDA for Eltrombopag Tablets,12.5 mg, 25 mg, 50 mg, and 75 mg". | |
| 13 January 2026 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 13, 2026, titled "Sentynl Therapeutics Inc. Announces FDA Approval of ZYCUBO® (copper histidinate)". | |
| 10 January 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 7 January 2026 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | Zydus Lifesciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 | |
| 2 January 2026 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 30 December 2025 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 27 December 2025 | Copy of Newspaper Publication | Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication | |
| 26 December 2025 | Updates | Zydus Lifesciences Limited has informed the Exchange regarding 'Intimation of ESG Rating'. | |
| 26 December 2025 | Trading Window | Zydus Lifesciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 | |
| 26 December 2025 | Copy of Newspaper Publication | Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication | |
| 24 December 2025 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 23 December 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 23, 2025, titled "Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®. NUFYMCO®. BLA has been approved by the USFDA". | |
| 19 December 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 19, 2025, titled "Zydus Lifesciences Limited signs an exclusive agreement with Myriad Genetics of US to launch cancer-risk assessment diagnostic tests in India". | |
| 16 December 2025 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 15 December 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 15, 2025, titled "Sentynl Therapeutics Announces FDA Acceptance of CUTX-101 NDA Resubmission". | |
| 12 December 2025 | Shareholders meeting | Zydus Lifesciences Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results along with copy of minutes. | |
| 10 December 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 10, 2025, titled "Zydus launches biosimilar Denosumab 120 mg SC protecting bone health in cancer patients". | |
| 9 December 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 09, 2025, titled "Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada". | |
| 4 December 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 04, 2025, titled "Zydus receives EIR for the injectable facility located at Jarod". | |
| 27 November 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 27, 2025, titled "Zydus receives tentative approval from USFDA for Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg". | |
| 26 November 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 26, 2025, titled "Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market.". | |
| 25 November 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 25, 2025, titled "Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg". | |
| 25 November 2025 | Investor Presentation | Zydus Lifesciences Limited has informed the Exchange about Investor Presentation | |
| 22 November 2025 | Copy of Newspaper Publication | Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication | |
| 19 November 2025 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 18 November 2025 | Copy of Newspaper Publication | Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication | |
| 17 November 2025 | Updates | Zydus Lifesciences Limited has informed the Exchange regarding 'Disclosures under SEBI (Prohibition of Insider Trading) Regulations, 2015'. | |
| 14 November 2025 | Copy of Newspaper Publication | Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication | |
| 14 November 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 14, 2025, titled "Zydus receives final approval from USFDA for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial". | |
| 13 November 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 13, 2025, titled "Closure of USFDA inspection at Zydus oncology injectable manufacturing facility in SEZ1, Ahmedabad". | |
| 13 November 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 13, 2025, titled "Revised press release". | |
| 13 November 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 13, 2025, titled "Zydus receives final approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg". | |
| 13 November 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 13, 2025, titled "Zydus Amplitude receives CE mark for its robotic surgical system Andy . | |
| 13 November 2025 | Analysts/Institutional Investor Meet/Con. Call Updates | Zydus Lifesciences Limited has informed the Exchange about Transcript | |
| 12 November 2025 | Copy of Newspaper Publication | Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication | |
| 11 November 2025 | Shareholders meeting | Zydus Lifesciences Limited has informed the Exchange regarding Notice of Postal Ballot | |
| 11 November 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 11, 2025, titled "Zydus receives approval from China s NMPA for Venlafaxine Extended-Release Capsules, 75 mg and 150 mg". | |
| 7 November 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 07, 2025, titled "Zydus receives tentative approval from USFDA for Olaparib Tablets, 100 mg and 150 mg". | |
| 7 November 2025 | Copy of Newspaper Publication | Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication | |
| 6 November 2025 | Analysts/Institutional Investor Meet/Con. Call Updates | Zydus Lifesciences Limited has informed the Exchange about Link of Recording | |
| 6 November 2025 | Investor Presentation | Zydus Lifesciences Limited has informed the Exchange about Investor Presentation | |
| 6 November 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 06, 2025, titled "Financial Performance for Q2 & H1 FY26". | |
| 6 November 2025 | Outcome of Board Meeting | Zydus Lifesciences Limited has informed the Exchange regarding Outcome of Board Meeting held on November 06, 2025. | |
| 6 November 2025 | Outcome of Board Meeting | Zydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025. | |
| 6 November 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 06, 2025, titled "Zydus receives USFDA Orphan Drug Designation (ODD) for Desidustat for the treatment of beta-thalassemia". | |
| 5 November 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 05, 2025, titled "Zydus receives EIR for SEZ II manufacturing facility, Ahmedabad". | |
| 4 November 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 04, 2025, titled "Zydus receives tentative approval from USFDA for Budesonide delayed release capsules, 4 mg". | |
| 1 November 2025 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 29 October 2025 | Analysts/Institutional Investor Meet/Con. Call Updates | Zydus Lifesciences Limited has informed the Exchange about Schedule of meet | |
| 29 October 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 29, 2025, titled "Zydus receives EIR for the Baddi manufacturing facility". | |
| 26 October 2025 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 24 October 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 24, 2025, titled "Press Release". | |
| 17 October 2025 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 14 October 2025 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | Zydus Lifesciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 | |
| 9 October 2025 | Copy of Newspaper Publication | Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication | |
| 6 October 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 06, 2025, titled "Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg". | |
| 6 October 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 06, 2025, titled "Zydus receives final approval from USFDA for Deflazacort oral suspension, 22.75 mg/mL". | |
| 4 October 2025 | Copy of Newspaper Publication | Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication | |
| 1 October 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 01, 2025, titled "Sentynl Therapeutics updates on its NDA for CUTX-101". | |
| 30 September 2025 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 27 September 2025 | Trading Window | Zydus Lifesciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 | |
| 25 September 2025 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 24 September 2025 | General Updates | Zydus Lifesciences Limited has informed the Exchange about General Updates | |
| 23 September 2025 | Press Release | Zydus Lifesciences Limited has informed the Exchange regarding a press release dated September 23, 2025, titled "Press Release". |
Regulation 30 of SEBI's listing regulations requires a company to tell the exchange of material events; the category is the exchange's, the words are the company's own summary as filed, cut to a few lines, and the PDF is the full filing.
Source
Corporate announcements on nseindia.com for ZYDUSLIFE.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.